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Abstract
Introduction: Pancreatic tumors usually display either a ductal, an acinar or an endocrine
differentiation. Mixed exocrine and endocrine pancreatic tumors are extremely rare. There have
been a few reports of the rare entity of mixed acinar-endocrine carcinoma of the pancreas, where
the endocrine cells represent more than 30% of the tumor. We herein describe a case of such a
pancreatic tumor in an asymptomatic patient.
Case presentation: A 74-year-old male patient with no evident clinical symptoms was referred for
surgical resection of a large mass located on the pancreatic head, which was confirmed by an
abdominal U/S, CT and MRI. FNA of the mass under endoscopic ultrasound guidance showed the
cytology specimen to comprise of cells with morphological and immunohistochemical characteristics
of endocrine pancreatic neoplasms. The patient underwent a modified Whipple’s procedure and his
post-operative course was uneventful. Pathological examination of the tumor revealed a mixed
acinar-endocrine carcinoma of the pancreas.
Conclusion: Mixed tumors of the pancreas are extremely rare and their clinical features and
pathogenesis remain unclear. The endocrine component seems to influence their prognosis favorably.
Therefore, aggressive surgical therapy remains the only well established line of treatment for these
tumors. Further accumulation of clinical cases will help clarify the clinical course and the optimal
therapy for these unusual tumors.
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Most pancreatic tumors arise as a single cell type, either
from the endocrine of exocrine pancreas, and can be
categorized into three types: ductal, acinar or endocrine.
[1–3] Acinar cell carcinoma (ACC) is a rare clinical entity,
accounting for only 1% of pancreatic exocrine tumors. [4]
Although it is well established that one-third of acinar
tumors may express neuroendocrine markers [5], their
endocrine component is usually limited to a few scattered
cells. When the endocrine cells exceed 25%–30% of the
tumor, the lesion is categorized as a mixed acinar-
endocrine carcinoma (MAEC). Since 1982, when Ulich
et al described this entity for the first time, less than 20
cases have been reported in the literature [6,7]. We report a
case of a 74-year-old man who underwent a Whipple’s
procedure for a large tumor of the pancreatic head that
proved to be a mixed acinar-endocrine carcinoma.
Case presentation
A 74-year-old, white male of Greek origin, was admitted in
our hospital in December 2008 in order to be treated for a
large mass located in the head of the pancreas. The patient
had been originally subjected to a routine blood check up,
which revealed mildly elevated transaminase levels. He
was then referred for an abdominal U/S and eventually for
aCTscanonanoutpatientbasis.Bothrevealedalarge,well
circumscribed mass of 6.8 cm in diameter, which seemed
tobeindirectcontactwiththeheadofthepancreasandthe
inferior vena cava (Figure 1). A subsequent MRI of the
abdomen showed the mass to measure about 7.3 cm, to
have irregular borders and to be located posterolaterally to
the pancreatic head. The inferior vena cava was located
directly behind the mass, and seemed to be slightly
displaced by the tumor. The portal vein was located
directly above the mass. Both these vessels did not appear
to be directly invaded by the mass.
Endoscopic ultrasound scan was performed which
allowed FNA of the mass. The cytology revealed cells
morphologically and immunogistologically indicative of a
neuroendocrine pancreatic neoplasm. Subsequently, the
patient was referred to our hospital for further surgical and
possible antiproliferative therapy.
On physical examination the patient was found to
manifest periodic choreo – athetosic movements that
had appeared in the 3 months that preceded the diagnosis
of his pancreatic tumor, to together with polyarthralgia of
his limbs’ large joints. The rest of his neurological clinical
examination as well as an MRI of the brain were normal.
Serum amylase, bilirubin and transaminase levels and all
serum tumor markers were within normal range.
The patient underwent surgical resection of the tumor by
means of a modified Whipple’s procedure and Roux-n-Y
reconstruction of the gastrointestinal tract (Figure 2). His
recovery was uneventful and he was discharged from the
hospital 10 days after the operation.
Pathological examination of the surgical specimen revealed
alargepancreatictumor,locatedintheheadofthepancreas,
measuring 12 × 9 × 6 cm. Microscopical examination
showed a malignantneoplasm with morphological features
of a mixed acinar-endocrine pancreatic tumor. The tumor
was multilobular, well circumscribed and fully encapsu-
lated. Numerous neoplastic emboli were present in the
vascular and lymphatic channels of the adjacent pancreatic
as well as peripancreatic fatty tissue and in the vessels of the
outer muscular layer of the duodenum, which was resected
en bloc with the tumor. Moreover, 9 out of 10 resected
lymph nodes harboured metastases of the neoplasm.
Immumohistochemistry revealed (Figures 3, 4) intense
positivity for chromogranin (25%), mild to intense
positivity for synaptophysin (20%), negativity for NSE,
C56,CK7,positivityfora1-antitrypsin(80%),expressionof
Ki-67 in 80% and no expression of p53.
The patient remains well 3 months after his operation,
with no evidence of recurrence. He also has a complete
remission of his neurological symptoms.
Discussion
The pancreas is well known to be composed from two
entirely different components, that is the exocrine and the
Figure 1.
CT scan image showing a large mass of 6.8 cm in diameter in
direct contact with the head of the pancreas and the inferior
vena cava (marked as 1 on the figure - marked as 2 & 3
coexisting simple kidney cysts).
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mainly from duct cells and secondly from acinar cells,
while the endocrine pancreas consists of islet cells.
Pancreatic tumors usually arise from one of these cell
types, resulting in either ductal adenocarcinomas (>75%
of pancreatic tumors), neuroendocrine carcinomas (about
7% of pancreatic tumors) and acinar cell carcinomas
(about 1%) [8].
Acinar cell tumors show a male predilection, they tend to
be larger than ductal adenocarcinomas and they are
usually diagnosed between the fifth and the seventh
decade of life [4,9]. Their most common location is the
head of the pancreas (56%), followed by the tail (36%)
and the body (8%). They usually present with non-specific
symptoms, such as anorexia, abdominal pain, nausea and
vomiting and weight loss. Jaundice is uncommon in ACC,
even when they are located in the head of the pancreas.
[4,9] Subcutaneous fat necrosis, paniculitis, polyarthralgia
Figure 2.
Diagrammatic depiction of the final Roux-en-Y reconstruction
(following a modified Whipple’s procedure).
(a) Hepaticojejunostomy, (b) Duodenojejunostomy,
(c) end-to-side duct to mucosa pancreatojejunostomy,
(d) end-to-side jejunojejunostomy.
Figure 3.
Histological section showing both the acinar and
neuroendocrine features of the pancreatic tumor
(Hematoxylin – eosin, × 120).
Figure 4.
(A) Histological section of the pancreatic tumor, showing
intense focal positive reaction to synaptophysin
(immunostain, × 120), (B) Histological section of the
pancreatic tumor showing diffuse positive immunoreaction
to a1-antitrypsin (immunostain, × 120).
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tumor secretes lipase. [11,12]
Surgical resection is the treatment of choice in these
tumors, which are found to demonstrate a higher
resectability rate of 64%, compared to that of ductal
adenocarcinoma (10–20%) [4]. Although data are limited
due to the rarity of these tumors, it appears that patients
with acinar cell carcinoma have a slightly better prognosis
than those suffering from ductal adenocarcinomas. How-
ever, although 1-year survival is just over 50%, ACC
remains a very aggressive tumor with an overall 5-year
survival of 5.9% [4,9]. Moreover, it has been suggested
that ACC is more aggressive than endocrine neoplasms.
The recurrence rate even after complete surgical resection is
high, suggesting that there are micrometastases present
even when the tumor appears to be well localized.
However, the results of adjuvant chemotherapy and
radiotherapy have been rather disappointing [7].
It is well known that up to one-third of acinar cell
carcinomas may express neuroendocrine markers [5,9],
which are usually limited to a few scattered cells.
Occasionaly, the endocrine cells may add up to more
than 30% of the tumor mass, in which case the neoplasm
is called a mixed acinar-endocrine carcinoma (MAEC).
Nowadays, many scientists believe that MAEC is a special
type of ACC, and its pathogenesis can be explained
embryologically. Specifically, the embryonic pancreas is
known to develop from the foregut and thereafter forms
ducts, acini and islets. Both exocrine and endocrine
pancreatic cells are thought to originate from multi-
potential epithelial cells [1,3].
Mixed acinar-endocrine carcinomas are usually large
tumors, located in the head of the pancreas (60% of the
cases). They usually become clinically evident in middle-
aged patients (mean age 58 years). Like ACC, MAEC has
no specific clinical symptoms. Patients complain of
jaundice, weight loss, vague abdominal pain and only
rarely do they present with an endocrine syndrome
[13,14]. Specifically in our case the patient complained
of choreo-athetosic movements of recent onset and
polyarthralgia that completely regressed after surgery,
leading us to speculate about the existence of a possible
causal relationship between his neurologic symptoms and
the pancreatic tumor. This, however, remains to be proven.
The only constant difference that is noted between ACC
and MAEC is the number of endocrine cells that they
contain. Most of the features, such us histological
differentiation, tumor size and location and nuclear p53
expression are comparable [5]. The only difference
reported in some series is the gender predominance,
which is mainly male for ACC and female in women.
However, considering the small number of MAEC’s
reported in the literature so far (less than 20) this
difference may well be incidental [3,5].
It must be noted that most of the cases reported so far refer
to tumors that were resected completely, thus allowing an
accurate diagnosis. It is impossible to define whether more
than 1/3 of a pancreatic tumor cells are neuroendocrine if
it can not be resected completely. Therefore, it may well be
that the true incidence of these tumors is underestimated.
The differentiation of ACC and MAEC from endocrine
neoplasms by means of standard histological techniques
can prove rather challenging. The presence of cells
containing periodic acid-Schiff positive granules which
are immunohistochemically positive for pancreatic
enzymes (such as trypsin, chymotrypsin and lipase) as
well as for endocrine markers (chromogranin and
synaptophysin), together with evidence of endocrine
hormones are indicative of tumor differentiation toward
both acinar and endocrine cell carcinoma [7]. Further-
more, it is easily understood that FNA cytology of these
tumors may be misleading as to their true histologic
nature, as was the case with our patient, as well. The
malignancy potential can be demonstrated by tumor
necrosis, numerous mitotic figures and the presence of
nuclear atypia with prominent nucleoli.
Regarding the prognosis of patients operated on for
MAEC, one report confirmed that out of the first 11
cases ever reported 4 patients died after 5 to 24 months of
diagnosis, while 6 were reported to be disease free 4 to 72
months following the primary diagnosis [3]. There has
also been a report of a patient with a MAEC that become
evident with symptoms of Zollinger-Ellison syndrome,
who died from disseminated carcinomatosis 24 years after
being operated on for the primary tumor [13]. Mean
survival after surgical resection of the primary tumor has
been calculated at 10.5 months [7].
Due to the small number of cases reported to date and the
relative lack of large scale follow-up data after operation,
there are still many controversies on the matter of the
optimal course of treatment. Surgery is the first line of
treatment in all the cases that the tumor proves to be
resectable, however there have been reports of patients
benefiting from surgical tumor debulking and local and
systemic antiproliferative therapy. It has been stated that
the presence of a neuroendocrine component may be
related to a more favorable outcome [15]. The rarity of this
pancreatic tumor makes it difficult to establish such a
relationship without a large multicentric study consisting
of a large number of patients. Therefore, aggressive surgery
should continue to be the gold standard of their treatment,
since it has been the one to demonstrate satisfactory long-
term survival results.
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